(Q33658606)

28 July 2017

title

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes (English)

1 reference

28 July 2017

3

Ludwig Kappos

1 reference

28 July 2017

12

Frederik Barkhof

1 reference

28 July 2017

2

Giancarlo Comi

1 reference

28 July 2017

1

Nicola De Stefano

1 reference

28 July 2017

5

Chris H Polman

1 reference

28 July 2017

Mark S Freedman

4

1 reference

28 July 2017

Bernard M J Uitdehaag

6

1 reference

28 July 2017

Brian Hennessy

7

1 reference

28 July 2017

Florence Casset-Semanaz

8

1 reference

28 July 2017

Lorenz Lehr

9

1 reference

28 July 2017

Bettina Stubinski

10

1 reference

28 July 2017

Dominic L Jack

11

1 reference

28 July 2017

language of work or name

English

0 references

publication date

29 November 2013

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

28 July 2017

published in

1 reference

28 July 2017

volume

85

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

647-653

1 reference

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Neuroimaging in multiple sclerosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033030

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 June 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-306289

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

21 January 2018

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for re

1 reference

12 December 2020

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP-2013-306289

1 reference

28 July 2017

1 reference

28 July 2017

1 reference